Portland, OR -- (SBWIRE) -- 02/27/2018 -- The growth of the global gynecological cancer drugs market is driven by factors such as increase in incidence of gynecological cancers, growth in importance of targeted drug therapies, rise in investment from government, public & private organizations for the development of novel drugs to treat cancer, and increase in risk factors that lead to cancer. However, high cost of drug development and threat of failure & adverse effects of cancer drug therapy restrain the growth of the market. Conversely, advancement of cancer drug research and advent of personalized medicine approach are expected to provide lucrative opportunities for the market expansion during the forecast period.

Early buyers will get 20% customization on this research report.

However, the market growth is hampered by high cost of drug development and threat of failure & adverse effects of cancer drug therapy. Conversely, advancement of cancer drug research and advent of personalized medicine approach are expected to provide numerous opportunities for market growth during the forecast period.

The cervical cancer segment is expected to maintain its dominant position during the analysis period, owing to increase in prevalence of cervical cancer globally.

Download the Sample PDF of Gynecological Cancer Drugs Industry Insights at: https://tinyurl.com/ycgxfxsg

Targeted therapy segment is expected to grow rapidly, registering a CAGR of 8.9% throughout the forecast period, owing to increased benefits of targeted therapy over chemotherapy.

For instance, combination therapy of gemcitabine with a platinum compound produced high response rates (as high as 71%) in patients suffering from ovarian cancer. Similarly, gemcitabine is used in combination with other compounds and cytotoxic agents for effective treatment of ovarian cancer. Popular combinations include gemcitabine with a platinum compound and paclitaxel, and gemcitabine with cisplatin or carboplatin. However, the standard approach of combination chemotherapy for treatment of epithelial ovarian cancer includes combination of a platinum compound, such as cisplatin or carboplatin, and a taxane, such as paclitaxel (Taxol) or docetaxel (Taxotere).

To reduce the burden of cancer, GCC member countries have established the Gulf Centre for Cancer Control and Prevention (GCCCP) that supports, services, and organizes programs for cancer control. In addition, it provides support services for the implementation of high-quality treatment care at all healthcare facilities in GCC states. GCCCP promotes cancer research in GCC member states through funding and collaboration with cancer research organizations.

Key Findings Of Gynecological Cancer Drugs Market:

1. The chemotherapy segment accounted for nearly two-thirds share of the global market in 2016.
2. Cervical cancer segment accounted for more than two-fifths share of the market in 2016.
3. The ovarian cancer segment is expected to grow at the fastest CAGR of 10.0% from 2016 to 2022.
4. Asia-Pacific is expected to be the fastest growing region, registering a CAGR of 9.8% during the forecast
period.

Do purchase inquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/3411

North America accounted for more than one-third share of the global market in 2016, and is expected to remain dominant throughout the forecast period. This is attributed to the increase in cancer incidence, growth in geriatric population, rise in patient awareness about the availability of treatment options, and favorable reimbursement framework for cancer drugs in the region. In addition, high adoption rate of cancer drugs and presence of highly sophisticated healthcare infrastructure are expected to present new growth opportunities to the players in this market.